THNR ETF
Amplify Weight Loss Drug & Treatment ETF
THNR ETF Overview
THNR ETF (Amplify Weight Loss Drug & Treatment ETF) is managed by Amplify ETFs with $5.8M in net assets. THNR expense ratio is 0.59%, holding 45 positions across sectors including Health Care, Financials. Inception date: 2024-05-21.
THNR performance shows a YTD return of 4.94%. The 1-year return is 17.89%. THNR dividend yield stands at 1.55%, paid annually.
THNR top holdings include Novo-Nordisk A/S-Spons Adr (8.8%), Eli Lilly & Co. (8.7%), Regeneron Pharmaceuticals, Inc. (6.2%), Innovent Biologics Inc (6.0%), CSPC Pharmaceutical Group Limited Shs (5.7%). Go to all THNR holdings, THNR sectors, or THNR dividends.
THNR can be compared against other funds. Use THNR overlap to find shared positions, or THNR vs another fund for a side-by-side view. THNR alternatives are available via the screener, along with tax-loss harvesting opportunities.